The Role of Bone Marrow Mesenchymal Stem Cells and Adipose Tissue-Derived Stem Cells in the Treatment of Liver Failure: A Literature Review
Liver disease is a major health problem that endangers human health worldwide. Stem cells have the unique ability to morph or differentiate into different types of cells within the body. In this way, stem cells can be used to seek out damaged liver tissue and regenerate the organ itself. Mesenchymal stem cells are multipotent stem cells that can self-renew and differentiate into different cell types. In other words, mesenchymal stem cells can become a variety of different cell types including adipose tissue, cartilage, muscle, tendon/ligament, bone, neurons, and hepatocytes. Many studies have shown that Mesenchymal stem cells play an essential role in liver recovery, and further research has verified the preliminary effectiveness and safety of these therapies. types of liver disease that are most suitable for MSC application should be determined, and the preparation and engraftment of MSCs should be standardized. Stem cell-based therapies will emerge as an effective treatment strategy for liver diseases in now and the future. Researchers conduct an examination of articles that are in accordance with the issue to be studied. Articles used in literature review are obtained through the database of international journal providers through PubMed, we investigated six clinical studies and discussed what happened in these clinical studies and the extent of the effectiveness of stem cells in treatment and whether the degree of liver disease had a role in the effectiveness of stem cells, we also discussed the mechanism of stem cells in treatment. One of six articles proved that Zeaxanthin dipalmitate (ZD) could enhance the defensive abilities against adverse stresses of human adipose-derived mesenchymal stem cells, One of six articles proved that infusion of allogeneic bone marrow-derived MSCs improving liver function and decreasing the incidence of severe infections. The rest articles proved that MSCs both Bone Marrow Stem cells (BMSCs) and Adipose Derived Stem Cells (ADSCs) are promising therapeutic agents for the liver fibrosis and cirrhosis treatment. In this review, we suggest that formulating and following treatment, Further studies are needed to determine the related mechanisms to enhance MSC efficacy.
J.E Till and E.A. McCulloch, “Hemopoietic stem cell differentiation”. Biochim Biophys Acta., 605: 431–459, 980.
I.L. Weissman, “Stem cells: units of development, units of regeneration, and units in evolution,” Cell., 100: 157–168, 2000.
J. Rossant, “Stem cells from the mammalian blastocyst,” Stem Cells., 19:477–482, 2001.
M.P De Miguel, S. Fuentes-Julian, Y. Alcaina, “Pluripotent stem cells: origin, maintenance and induction,” Stem Cell Rev., 6:633– 649, 2010.
A. Augello, T.B. Kurth, B.C. De,” Mesenchymal stem cells: a perspective from in vitro cultures to in vivo migration and niches,’ Eur Cell Mater, 20:121–133, 2010.
B. Beck and C. Blanpain,” Mechanisms regulating epidermal stem cells,” EMBO J, 31:2067– 2075, 2012.
M.J. Evans and M.H. Kaufman,” Establishment in culture of pluripotential cells from mouse embryos,” Nature, 292:154–156, 1981.
S. Ilancheran, Y. Moodley, U. Manuelpillai,” Human fetal membranes: a source of stem cells for tissue regeneration and repair,” Placenta, 30:2–10, 2009.
Y. Jiang, B. N. Jahagirdar, R. L. Reinhardt, R. E. Schwartz, C. D. Keene, X. Ortiz-Gonzalez, R., “Pluripotency of mesenchymal stem cells derived from adult marrow,” Nature, 418, 41–49, 2002.
A. J. Friedenstein, R. K. Chailakhjan, and K. S. Lalykina, “The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells,” Cell Tissue Kinet. 3, 393–403, , 1970.
L. da Silva Meirelles, P. C. Chagastelles, and N. Nardi, B., “Mesenchymal stem cells reside in virtually all post-natal organs and tissues,” J. Cell Sci. 119, 2204–2213, 2006.
D.C. Colter, I. Sekiya, D.J. Prockop,” Identification of a subpopulation of rapidly self-renewing and multipotential adult stem cells in colonies of human marrow stromal cells,” PNAS. 98:7841-7845, 2001.
D.A. Rennerfeldt and K.J. van Vliet Concise review: “When colonies are not clones: Evidence and implications of Intracolony heterogeneity in mesenchymal stem cells,” Stem cells (Dayton, Ohio). 34:1135-114, 2016.
M. Dominici, K. Le Blanc, I. Mueller, I., Marini F Slaper-Cortenbach., D. Krause, “Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement,” Cytotherapy, 8:315-317, 2006.
F.J. Lv, R.S. Tuan, K.M.C. Cheung, V.Y.L. Leung, “The surface markers and identity of human mesenchymal stem cells,” Stem cells (Dayton, Ohio). 32:1408-1419, 2014.
J. Neuberger, “Liver transplantation in the United Kingdom,” Liver Transpl, 22(8):1129–35, 2016.
M.P. de Miguel, I. Prieto, A. Moratilla, “Mesenchymal Stem Cells for Liver Regeneration in Liver Failure: From Experimental Models to Clinical Trials,” Stem Cells Int, 2019:3945672, 2019.
Z.H. Zhang, W. Zhu, H.Z. Ren, “Mesenchymal stem cells increase expression of heme oxygenase-1 leading to anti-inflammatory activity in treatment of acute liver failure,” Stem Cell Res Ther, 8:70. 2017.  Y. Wang, J.L. Wang, H.C. Ma, Z.T. Tang, H.R. Ding, X.L. Shi,” Mesenchymal stem cells increase heme oxygenase 1-activated autophagy in treatment of acute liver failure,” Biochem Biophys Res Commun., 508:682e689, 2019.
S. Naseem, T. Hussain, S. Manzoor,” Interleukin-6: a promising cytokine to support liver regeneration and adaptive immunity in liver pathologies,” Cytokine Growth Factor Rev., 39:36e45, 2018.
M. Liu, J. Yang, W. Hu, S. Zhang, Y. Wang, “Superior performance of co-cultured mesenchymal stem cells and hepatocytes in poly(lactic acid-glycolic acid) scaffolds for the treatment of acute liver failure,” Biomed Mater., 11, 015008, 2016.
A. Banas, T. Teratani, Y. Yamamoto,” IFATS collection: in vivo therapeutic potential of human adipose tissue mesenchymal stem cells after transplantation into mice with liver injury,”. Stem Cells, 26:2705e2712, 2008.
X. Guan, N. Wang, F. Cui, “Caveolin-1 is essential in the differentiation of human adipose-derived stem cells into hepatocyte-like cells via an MAPK pathway-dependent mechanism,” Mol Med Rep, 13:1487e1494, 2016.
W.P. Tang, T. Akahoshi, J.S. Piao, “Basic fibroblast growth factor-treated adipose tissue-derived mesenchymal stem cell infusion to ameliorate liver cirrhosis via paracrine hepatocyte growth factor,” J Gastroenterol Hepatol., 30:1065e1074, 2015.
F. Salomone, I. Barbagallo, L. Puzzo, C. Piazza, G. Li Volti, “Efficacy of adipose tissue-mesenchymal stem cell transplantation in rats with acetaminophen liver injury,” Stem Cell Res., 11:1037e1044, 2013.
Y.J. Huang, P. Chen, C.Y. Lee, “Protection against acetaminophen-induced acute liver failure by omentum adipose tissue derived stem cells through the mediation of Nrf2 and cytochrome P450 expression,”. J Biomed Sci., 23: 5, 2016.
J.C. Kim and G. Tae, “The modulation of biodistribution of stem cells by anchoring lipid-conjugated heparin on the cell surface,” J Control Release,217: 128e137, 2015.
Y. Hwang, J.C. Kim, G. Tae, “Significantly enhanced recovery of acute liver failure by liver targeted delivery of stem cells via heparin functionalization,” Biomaterials., 209:67e78, 2019.
Y. Liu, Y. Xiong, F. Xing, H. Gao, X. Wang, L. He, C. Ren, L. Liu, K.F. So, J. Xiao, “Precise Regulation of miR-210 Is Critical for the Cellular Homeostasis Maintenance and Transplantation Efficacy Enhancement of Mesenchymal Stem Cells in Acute Liver Failure Therapy,” Cell Transplant, 9;26(5):805-820, 2017.
M. Shi, Z. Zhang, R. Xu, “Human mesenchymal stem cell transfusion is safe and improves liver function in acute-on-chronic liver failure patients,” Stem Cells Transl Med. 1(10):725-731, 2012.
F.C. Schacher, A. Martins Pezzi da Silva, L.M.D.R. Silla, M.R. Álvares-da-Silva, “Bone Marrow Mesenchymal Stem Cells in Acute-on-Chronic Liver Failure Grades 2 and 3: A Phase I-II Randomized Clinical Trial,” Can J Gastroenterol Hepatol, 4;2021:3662776, 2021.
B.L. Lin, J.F. Chen, W.H. Qiu, K.W. Wang, D.Y. Xie, X.Y. Chen, Q.L. Liu, L. Peng, J.G. Li, Y.Y. Mei, W.Z. Weng, Y.W. Peng, H.J. Cao, J.Q. Xie, S.B. Xie, A.P. Xiang, Z.L. Gao, ‘Allogeneic bone marrow-derived mesenchymal stromal cells for hepatitis B virus-related acute-on-chronic liver failure: A randomized controlled trial,” Hepatology, 66(1):209-219, 2017
H. Salama, A.R. Zekri, E. Medhat, S.A. Al Alim, O.S. Ahmed, A.A. Bahnassy, M.M. Lotfy, R. Ahmed, S. Musa, “Peripheral vein infusion of autologous mesenchymal stem cells in Egyptian HCV-positive patients with end-stage liver disease,” Stem Cell Res Ther., 28;5(3):70, 2014.
M.E. Amer, S.Z. El-Sayed, W.A. El-Kheir, H. Gabr, A.A. Gomaa, N. El-Noomani, M. Hegazy, “Clinical and laboratory evaluation of patients with end-stage liver cell failure injected with bone marrow-derived hepatocyte-like cells,” Eur J Gastroenterol Hepatol., 23(10):936-41, 2011.
M. Mohamadnejad, K. Alimoghaddam, M., Bagheri, “Randomized placebo-controlled trial of mesenchymal stem cell transplantation in decompensated cirrhosis,” Liver Int., 33:1490–1496, 2013.
P.J. Mishra, P.J. Mishra, R. Humeniuk, “Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells,” Cancer Res, 68:4331–4339, 2008.
Y.F. Zhou, M. Bosch-Marce, H. Okuyama, “Spontaneous transformation of cultured mouse bone marrow-derived stromal cells,” Cancer Res. 66:10849–10854, 2006.
How to Cite
Copyright (c) 2022 Mohamed Ziedan, Maha Ayman, Dina Mohamed
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.